A61K 40/11
T-cells
Official title: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
A61K40/11 (T-cells) appears on 4,739 US grants and 11,041 published applications in this corpus.
Search patents in A61K- Granted patents
- 4,739
- Published applications
- 11,041
- Assignees
- 2,415
- Inventors
- 13,437
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 3 | 0 |
| 1990 | 2 | 0 |
| 1991 | 2 | 0 |
| 1992 | 5 | 0 |
| 1993 | 4 | 0 |
| 1994 | 7 | 0 |
| 1995 | 4 | 0 |
| 1996 | 4 | 0 |
| 1997 | 8 | 0 |
| 1998 | 21 | 0 |
| 1999 | 12 | 0 |
| 2000 | 14 | 0 |
| 2001 | 18 | 12 |
| 2002 | 25 | 94 |
| 2003 | 26 | 112 |
| 2004 | 27 | 103 |
| 2005 | 22 | 69 |
| 2006 | 34 | 73 |
| 2007 | 18 | 57 |
| 2008 | 34 | 107 |
| 2009 | 29 | 104 |
| 2010 | 60 | 143 |
| 2011 | 56 | 162 |
| 2012 | 61 | 100 |
| 2013 | 77 | 116 |
| 2014 | 86 | 193 |
| 2015 | 101 | 158 |
| 2016 | 124 | 254 |
| 2017 | 115 | 389 |
| 2018 | 211 | 499 |
| 2019 | 291 | 756 |
| 2020 | 413 | 935 |
| 2021 | 431 | 1087 |
| 2022 | 434 | 1233 |
| 2023 | 435 | 1153 |
| 2024 | 536 | 1266 |
| 2025 | 571 | 1047 |
| 2026 | 417 | 819 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Anti-Claudin18.2 antigen-binding fragment or antibody, and use thereof182551196 Oct 2026US 12,751,972 B2Guangzhou Bio-Gene Technology Co., Ltd
- Bispecific chimeric antigen receptors targeting CD20 and BCMA6 Oct 2026US 12,751,973 B2Abelzeta Inc.
- BCMA chimeric antigen receptors6 Oct 2026US 12,752,006 B2Regeneron Pharmaceuticals, Inc.
- Dual CAR expressing T cells individually linked to CD28 and 4-1BB6 Oct 2026US 12,753,218 B2The Trustees of the University of Pennsylvania
- CCR4 targeted chimeric antigen receptor modified T cells for treatment of CCR4 positive malignancies6 Oct 2026US 12,753,219 B2City of Hope
- Inverse agonists of rar related orphan receptors (rors)8 Oct 2026US 2026/0306484 A111949098 CANADA INC. (NUREDCO) c/o Jean I. TCHERVENKOV
- Composition for inducing immunotolerance8 Oct 2026US 2026/0306540 A1
- Novel phosphoantigen prodrug compound and use thereof8 Oct 2026US 2026/0306541 A1
- Targeted Immune Cell Therapy Utilizing TRAIL and TNF Mediated Apoptosis8 Oct 2026US 2026/0306542 A1Northeastern University
- Intra-striatal co-transplantation of autologous treg and mda cells in parkinson's disease cell therapy8 Oct 2026US 2026/0306543 A1The McLean Hospital Corporation
Most cited
By later US patents
- Gene therapy759US 5,399,346 AThe United States of America as represented by the Department of Health and Human Services · 1995
- Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells512US 6,352,694 B1Genetics Institute, Inc. · 2002
- Methods for selectively stimulating proliferation of T cells452US 6,534,055 B1Genetics Institute, Inc. · 2003
- Methods of treating HIV infected subjects386US 6,905,680 B2Genetics Institute, Inc. · 2005
- Methods for selectively stimulating proliferation of T cells385US 6,887,466 B2Genetics Institute, Inc. · 2005